Published in Eur Radiol on May 08, 2013
Future directions for the early detection of recurrent breast cancer. J Cancer (2014) 0.95
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014. Breast Care (Basel) (2014) 0.91
Multiparametric MR Imaging of Breast Cancer. Magn Reson Imaging Clin N Am (2016) 0.86
Early prediction of response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and gray-scale ultrasonography. Oncol Rep (2014) 0.79
Sequence design and evaluation of the reproducibility of water-selective diffusion-weighted imaging of the breast at 3 T. NMR Biomed (2014) 0.77
PET/MR in invasive ductal breast cancer: correlation between imaging markers and histological phenotype. Br J Cancer (2017) 0.75
Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer. Eur Radiol (2016) 0.75
Texture analysis on MR images helps predicting non-response to NAC in breast cancer. BMC Cancer (2015) 0.75
Multiparametric and Multimodality Functional Radiological Imaging for Breast Cancer Diagnosis and Early Treatment Response Assessment. J Natl Cancer Inst Monogr (2015) 0.75
Diffusion-weighted breast MRI: Clinical applications and emerging techniques. J Magn Reson Imaging (2016) 0.75
The Efficiency of Diffusion Weighted MRI and MR Spectroscopy On Breast MR Imaging. J Breast Health (2013) (2014) 0.75
Intravoxel incoherent motion (IVIM) histogram biomarkers for prediction of neoadjuvant treatment response in breast cancer patients. Eur J Radiol Open (2017) 0.75
Diffusion magnetic resonance imaging: A molecular imaging tool caught between hope, hype and the real world of "personalized oncology". World J Radiol (2017) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer (1957) 21.59
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol (2011) 13.95
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol (2007) 6.80
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol (2008) 6.31
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol (2009) 4.66
A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A (1995) 2.70
Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging (2006) 2.69
Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. Magn Reson Imaging (2006) 2.26
Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg (1995) 2.20
Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer (2002) 2.18
MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol (2005) 2.06
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. J Clin Oncol (2009) 1.99
Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology (2010) 1.98
Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res (2008) 1.95
Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed (2009) 1.91
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res Treat (2010) 1.73
Diffusion-weighted MR for differentiation of breast lesions at 3.0 T: how does selection of diffusion protocols affect diagnosis? Radiology (2009) 1.67
Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat (2004) 1.62
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol (1993) 1.58
What is the current standard of care for anti-HER2 neoadjuvant therapy in breast cancer? Oncology (Williston Park) (2012) 1.50
A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res (2010) 1.50
Locally advanced and inflammatory breast cancer. J Clin Oncol (2008) 1.44
Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol (2011) 1.44
Diffusion-weighted imaging of the breast: principles and clinical applications. Radiographics (2011) 1.29
Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings. Radiology (2010) 1.26
Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast (2011) 1.21
Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Acta Oncol (2010) 1.21
Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR Am J Roentgenol (2008) 1.20
Assessment of breast lesions with diffusion-weighted MRI: comparing the use of different b values. AJR Am J Roentgenol (2009) 1.18
Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol (2010) 1.17
Diffusion weighted imaging in breast MRI: comparison of two different pulse sequences. Acad Radiol (2007) 1.16
Invasive ductal carcinoma: correlation of apparent diffusion coefficient value with pathological prognostic factors. NMR Biomed (2010) 1.14
MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy. J Magn Reson Imaging (2007) 1.13
Diffusion tensor MRI: preliminary anisotropy measures and mapping of breast tumors. J Magn Reson Imaging (2010) 1.12
Correlations between diffusion-weighted imaging and breast cancer biomarkers. Eur Radiol (2012) 1.10
Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene (1997) 1.09
Diffusion tensor magnetic resonance imaging of the normal breast. Magn Reson Imaging (2010) 1.09
Comparison of diffusion-weighted MR imaging and FDG PET/CT to predict pathological complete response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol (2011) 1.07
Clinicopathological characteristics of triple-negative breast cancers. Breast Cancer (2009) 1.03
Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. PLoS One (2012) 1.01
Intravoxel incoherent motion imaging using steady-state free precession. Magn Reson Med (1988) 1.00
The triple-negative subtype: new ideas for the poorest prognosis breast cancer. J Natl Cancer Inst Monogr (2011) 1.00
Diffusion tensor magnetic resonance imaging of the breast: a pilot study. Eur Radiol (2010) 0.99
The role of mean diffusivity (MD) as a predictive index of the response to chemotherapy in locally advanced breast cancer: a preliminary study. Eur Radiol (2009) 0.95
DW-MRI ADC values can predict treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. Med Oncol (2011) 0.94
Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. Gan To Kagaku Ryoho (2009) 0.94
Pre-treatment differences and early response monitoring of neoadjuvant chemotherapy in breast cancer patients using magnetic resonance imaging: a systematic review. Eur Radiol (2012) 0.88
Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg Clin North Am (2003) 0.88
Sometimes a great notion--an assessment of neoadjuvant systemic therapy for breast cancer. J Natl Cancer Inst (2005) 0.87
Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study. BMC Cancer (2011) 0.81
High incidence and frequency of LOH are associated with aggressive features of high-grade HER2 and triple-negative breast cancers. Breast Cancer (2010) 0.79
Role of Magnetic Resonance Imaging in the prediction of tumor response in patients with locally advanced breast cancer receiving neoadjuvant chemo-therapy. Radiol Med (2003) 0.79
Continuous flow-driven inversion for arterial spin labeling using pulsed radio frequency and gradient fields. Magn Reson Med (2008) 5.23
Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg (2004) 5.10
Cross sectional study of conventional cervical smear, monolayer cytology, and human papillomavirus DNA testing for cervical cancer screening. BMJ (2003) 3.42
A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res (2007) 2.88
Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol (2006) 2.71
Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg (2006) 2.49
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol (2013) 2.39
Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res (2008) 2.16
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med (2007) 2.00
Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer. Breast Cancer Res Treat (2012) 1.97
Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst (2012) 1.96
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat (2011) 1.89
Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging (2010) 1.87
Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity. Diabetes Care (2007) 1.77
18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. J Nucl Med (2012) 1.73
Deep pelvic endometriosis: MR imaging for diagnosis and prediction of extension of disease. Radiology (2004) 1.72
Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res (2004) 1.68
Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med (2013) 1.67
Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res (2007) 1.58
Performance of FDG PET/CT in the clinical management of breast cancer. Radiology (2012) 1.54
Hippocampal hyperperfusion in Alzheimer's disease. Neuroimage (2008) 1.49
Lymphoscintigraphy can select breast cancer patients for internal mammary chain radiotherapy. Int J Radiat Oncol Biol Phys (2011) 1.49
Ocular adnexal lymphoma and Helicobacter pylori gastric infection. Am J Hematol (2010) 1.45
Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat (2008) 1.42
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer. J Clin Oncol (2012) 1.39
The CD10 enzyme is a key player to identify and regulate human mammary stem cells. Stem Cells (2010) 1.34
Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys (2008) 1.34
(18)F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging (2010) 1.30
Frequent genomic structural alterations at HPV insertion sites in cervical carcinoma. J Pathol (2010) 1.30
TP53 status and response to chemotherapy in breast cancer. Pathobiology (2008) 1.28
Expert opinions on positron emission tomography and computed tomography imaging in lymphoma. Oncologist (2009) 1.25
Gastric metastasis of breast cancer: a single centre retrospective study. Dig Liver Dis (2011) 1.21
Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer. Cancer Res (2009) 1.19
Ocular adnexal lymphoma: a review of clinicopathologic features and treatment options. Blood (2006) 1.19
Automated microdroplet platform for sample manipulation and polymerase chain reaction. Anal Chem (2006) 1.17
The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med (2011) 1.13
Early modifications of hepatic perfusion measured by functional CT in a rat model of hepatocellular carcinoma using a blood pool contrast agent. Eur Radiol (2004) 1.13
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat (2010) 1.13
Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim. Eur J Nucl Med Mol Imaging (2011) 1.11
Implications of circadian clocks for the rhythmic delivery of cancer therapeutics. Adv Drug Deliv Rev (2007) 1.11
Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene (2002) 1.10
Two types of squamous cell carcinoma of the palatine tonsil characterized by distinct etiology, molecular features and outcome. Cancer Lett (2007) 1.07
Imatinib mesylate as a preoperative therapy in dermatofibrosarcoma: results of a multicenter phase II study on 25 patients. Clin Cancer Res (2010) 1.07
p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast (2013) 1.05
Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer (2012) 1.04
The sentinel node procedure in breast cancer: nuclear medicine as the starting point. J Nucl Med (2011) 1.03
Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer (2009) 1.01
Contamination-free continuous flow microfluidic polymerase chain reaction for quantitative and clinical applications. Anal Chem (2005) 1.01
Should FDG PET/CT be used for the initial staging of breast cancer? Eur J Nucl Med Mol Imaging (2009) 1.00
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. Cancer Res (2009) 0.99
Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation. Blood (2008) 0.98
Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br J Clin Pharmacol (2011) 0.97
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist (2010) 0.97
Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. Oncologist (2006) 0.96
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer (2013) 0.95
The aurora B kinase inhibitor AZD1152 sensitizes cancer cells to fractionated irradiation and induces mitotic catastrophe. Cell Cycle (2009) 0.94
Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res (2013) 0.92
Fertility in young women after chemotherapy with alkylating agents for Hodgkin and non-Hodgkin lymphomas. Hematol J (2003) 0.92
Prediction of overall survival through circadian rest-activity monitoring during chemotherapy for metastatic colorectal cancer. Int J Cancer (2012) 0.92
Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol (2010) 0.92
Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging (2015) 0.92
Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts. Mol Cancer Ther (2012) 0.91
Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy. J Hematol Oncol (2013) 0.91
Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. J Hematol Oncol (2010) 0.90
Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial. Breast Cancer Res Treat (2013) 0.90
Human skin carcinoma arising from kidney transplant-derived tumor cells. J Clin Invest (2013) 0.89
Feasibility and clinical outcome of laparoscopic colorectal resection for endometriosis. Am J Obstet Gynecol (2005) 0.88
Invasive pulmonary infection due to Trichoderma longibrachiatum mimicking invasive Aspergillosis in a neutropenic patient successfully treated with voriconazole combined with caspofungin. Clin Infect Dis (2008) 0.87
Real-time quantitative PCR determination of urokinase-type plasminogen activator receptor (uPAR) expression of isolated micrometastatic cells from bone marrow of breast cancer patients. Int J Cancer (2005) 0.87
Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience. PLoS One (2013) 0.86
Value of cytogenetic analysis in the treatment of dermatofibrosarcoma protuberans. J Clin Oncol (2008) 0.86
Brentuximab vedotin in heavily treated Hodgkin and anaplastic large-cell lymphoma, a single centre study on 45 patients. Br J Haematol (2014) 0.86
Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. Int J Cancer (2007) 0.86
Prediction of survival by neutropenia according to delivery schedule of oxaliplatin-5-Fluorouracil-leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). Chronobiol Int (2011) 0.85
Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis. Cancer Chemother Pharmacol (2013) 0.85
Comprehensive model for simultaneous MRI determination of perfusion and permeability using a blood-pool agent in rats rhabdomyosarcoma. Eur Radiol (2005) 0.85
Donor-derived keratinocytes in actinic keratosis and squamous cell carcinoma in patients with kidney transplant. J Invest Dermatol (2012) 0.84